EC expands Zytiga to chemotherapy-naïve CRPC patients

The European Commission approved a label expansion for Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ) to include use in chemotherapy-naïve patients with metastatic castration-resistant p...